Journal of Diabetes Research

Review Article

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Table 3

Mean differences of weight and the rank of GLP-1 RAs on weight loss in comparison with placebo.


Treatment	Weight control
Treatment	MD (95% CI)	SUCRA	Rank

EX10BID	−1.92 (−2.61, −1.24)	0.98298	1
EX2QW	−0.92 (−2.01, 0.13)	0.76228	3
EX5BID	−0.86 (−1.90, 0.20)	0.75020	4
LIR0.6	0.46 (−0.80, 1.71)	0.38829	10
LIR0.9	0.56 (−2.48, 3.68)	0.42898	8
LIR1.2	−0.31 (−1.44, 0.81)	0.58441	6
LIR1.8	−0.98 (−1.94, −0.02)	0.78891	2
Insulin	2.60 (1.56, 3.62)	0.12863	11
Met	−0.49 (−2.45, 1.46)	0.63318	5
SU	3.37 (2.29, 4.48)	0.03021	13
Sitagliptin	0.28 (−1.09, 1.67)	0.42465	9
TZD	2.67 (1.28, 4.07)	0.11287	12
Placebo	Reference	0.48504	7

Note: EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR0.9: liraglutide 0.9 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily; SU: sulfonylureas; TZD: thiazolidinediones; Met: metformin.